AlphAIAlphAI — Financial news for AI agents
pulse2.comOCT 62 min read

Insmed CFO Sara Bonstein To Step Down As Company Reaffirms 2026 Guidance

Insmed's CFO Sara Bonstein will step down on October 30, 2026, after nearly seven years. The company reaffirmed its 2026 guidance, expecting BRINSUPRI revenue of $1.25B-$1.40B and ARIKAYCE revenue of $450M-$470M. Insmed plans to report Q3 2026 results on October 29 and has begun a search for a new CFO.

Original reporting
pulse2.com
Published Oct 6, 2026, 5:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 7:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Insmed CFO Sara Bonstein To Step Down As Company Reaffirms 2026 Guidance — source image
Source · pulse2.com
Decision brief

The 30-second read

Low
01

Why it matters

The CFO departure is a material corporate event but guidance remains unchanged, suggesting limited immediate price impact.

02

Market read

Executive change with reaffirmed guidance; modest relevance for traders monitoring biotech leadership.

03

What to watch

Insmed's strong cash flow outlook and product launches may offset leadership concerns.

Relevance 7/10Novelty 6/10Timing: today

Background

Insmed is a biotech firm with products BRINSUPRI and ARIKAYCE, recently reaffirming its 2026 guidance.

Market effects

Sector

May prompt scrutiny of other biotech CFOs and governance practices.

Regional

Limited to US biotech sector.

Global

Low global impact.

Counterpoint

What could challenge this read

The CFO change could be seen as a positive sign of upcoming strategic shifts.

Key entities

  • company
    Insmed

    US-listed biotech company (NASDAQ: ISMD).

  • person
    Sara Bonstein

    Outgoing CFO of Insmed.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 12
$INSMMed

BofA cuts Insmed stock price target on valuation concerns

BofA Securities reduced its price target for Insmed (INSM) to $207 from $214, citing valuation concerns, while maintaining a Buy rating. The company reported strong performance for Brinsupri, with revenue growth of 186% over the last twelve months and raised fiscal 2026 guidance to $1.25B-$1.4B. Insmed shares have fallen 42% year-to-date, with a market cap of $21.97B. Analysts anticipate sales growth and potential market expansion.

investing.com2 min
OCT 8
$INSMMed

UBS reiterates Insmed stock rating on Brinsupri sales outlook

UBS maintained a Buy rating on Insmed (INSM) with a $172 price target, despite lowering Brinsupri sales estimates for 2H 2026. The stock is down 41.5% YTD. UBS cites compelling valuation and peak sales potential over $5B. Other analysts also show positive sentiment, with recent regulatory approvals in Japan and a U.S. FDA priority review for Arikayce.

investing.com2 min
OCT 6
$INSMMed

BMO Capital reiterates Insmed stock rating on CFO transition

BMO Capital reiterated an Outperform rating and $192 price target for Insmed (INSM) after the company announced its CFO will step down. The stock trades at $101.79 with a $22.25B market cap. Insmed confirmed its 2026 guidance, and BMO noted the transition should have limited impact. Recent analyst actions include Goldman Sachs' Buy rating with a $188 target and Mizuho's increased target to $195.

investing.com2 min
OCT 5
$INSMHigh

Why is Insmed stock sliding today?

Insmed (INSM) stock fell 6.3% after CFO Sara Bonstein announced her departure in October 2026. The company reaffirmed 2026 revenue guidance of $1.25B–$1.40B for BRINSUPRI and $450M–$470M for ARIKAYCE. The decline was attributed to leadership uncertainty ahead of the Q3 earnings report, despite analyst optimism and a constructive broader market.

investing.com2 min
OCT 5
$INSMMed

Insmed stock falls as CFO Sara Bonstein to step down

Insmed Inc (INSM) shares dropped 8% after announcing CFO Sara Bonstein will step down on October 30. The company is searching for a new CFO and reaffirmed its 2026 financial guidance. Bonstein's departure is not related to any disagreements with the company. Insmed expects cash flow positivity next year. The company will report Q3 2026 results on October 29.

investing.com2 min